Furthermore, Glo1 emerged as an independent prognosticator of adverse significance in a colorectal cancer (CRC) patient cohort (37), later confirmed by the study showing that patients with low Glo1-expressing CRC had longer disease-free survival than the patients whose tumor expressed higher levels of Glo1 (39). Here, GLO1 is linked to neoplasm.